

EIF2B3 Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP1930b

Specification

EIF2B3 Antibody (N-term) Blocking Peptide - Product Information

Primary Accession

Q9HA31

EIF2B3 Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 8891

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP1930b was selected from the N-term region of human EIF2B3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

EIF2B3 Antibody (N-term) Blocking Peptide - Protein Information

Name EIF2B3 {ECO:0000313|EMBL:CAG33566.1}

Cellular Location

Cytoplasm, cytosol {ECO:0000256|ARBA:ARBA00004514}

EIF2B3 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.


• Blocking Peptides

EIF2B3 Antibody (N-term) Blocking Peptide - Images

EIF2B3 Antibody (N-term) Blocking Peptide - Background

EIF2B3 catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP. Mutations in each of the five subunits of translation initiation factor eIF2B, including subunit 3, can cause







leukoencephalopathy with vanishing white matter. EIF2B3 has also been identified as a cofactor of hepatitis C virus internal ribosome entry site-mediated translation.

EIF2B3 Antibody (N-term) Blocking Peptide - References

van der Knaap, M.S., et al., Ann. Neurol. 51(2):264-270 (2002). Kruger, M., et al., Proc. Natl. Acad. Sci. U.S.A. 97(15):8566-8571 (2000). Gomez, E., et al., Mol. Cell. Biol. 20(11):3965-3976 (2000).